Literature DB >> 29890249

Origins based clinical and molecular complexities of epithelial ovarian cancer.

Thingreila Muinao1, Mintu Pal2, Hari Prasanna Deka Boruah1.   

Abstract

Ovarian cancer is the most lethal of all common gynaecological malignancies in women worldwide. Ovarian cancer comprises of >15 distinct tumor types and subtypes characterized by histopathological features, environmental and genetic risk factors, precursor lesions and molecular events during oncogenesis. Recent studies on gene signature profiling of different subtypes of ovarian cancer have revealed significant genetic heterogeneity between and within each ovarian cancer histological subtype. Thus, an immense interest have shown towards a more personalized medicine for understanding the clinical and molecular complexities of four major types of epithelial ovarian cancer (serous, endometrioid, clear cell, and mucinous). As such, further in depth studies are needed for identification of molecular signalling network complexities associated with effective prognostication and targeted therapies to prevent or treat metastasis. Therefore, understanding the metastatic potential of primary ovarian cancer and therapeutic interventions against lethal ovarian cancer for the development of personalized therapies is very much indispensable. Consequently, in this review we have updated the key dysregulated genes of four major subtypes of epithelial carcinomas. We have also highlighted the recent advances and current challenges in unravelling the complexities of the origin of tumor as well as genetic heterogeneity of ovarian cancer.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical and molecular complexities; Genetic heterogeneity; Ovarian cancer

Mesh:

Year:  2018        PMID: 29890249     DOI: 10.1016/j.ijbiomac.2018.06.036

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  8 in total

1.  A BRCA1 Splice Site Variant Responsible for Familial Ovarian Cancer in a Han-Chinese Family.

Authors:  Peng-Zhi Hu; Xiang-Yu Chen; Wei Xiong; Zhi-Jian Yang; Xiao-Rong Li; Wen-Zhi Deng; Li-Na Gong; Hao Deng; La-Mei Yuan
Journal:  Curr Med Sci       Date:  2022-03-15

2.  MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer.

Authors:  Yike Li; Wanjia Tian; Hong Zhang; Zhijian Zhang; Qinghe Zhao; Lei Chang; Ningjing Lei; Weiwei Zhang
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

3.  Inhibition of long non-coding RNA XIST upregulates microRNA-149-3p to repress ovarian cancer cell progression.

Authors:  Rong Jiang; Hongyu Zhang; Jinhua Zhou; Juan Wang; Yuejuan Xu; He Zhang; Yanzheng Gu; Fengqing Fu; Yu Shen; Guangbo Zhang; Lanlan Feng; Xueguang Zhang; Youguo Chen; Fangrong Shen
Journal:  Cell Death Dis       Date:  2021-02-01       Impact factor: 8.469

4.  LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis.

Authors:  Yue Wu; Ting Wang; Lin Xia; Mei Zhang
Journal:  Cancer Cell Int       Date:  2021-05-29       Impact factor: 5.722

5.  H3K27ac-activated lncRNA KTN1-AS1 aggravates tumor progression by miR-505-3p/ZNF326 axis in ovarian cancer.

Authors:  Xiaohui Xie; Qirong Wen; Xu Yang; Weiwei Chen; Yaqiong Liu; Wenjie Liu; Tiansong Zhang; Cuiyi Xu; Kun Shi
Journal:  Ann Transl Med       Date:  2022-05

Review 6.  Multi-biomarker panel signature as the key to diagnosis of ovarian cancer.

Authors:  Thingreila Muinao; Hari Prasanna Deka Boruah; Mintu Pal
Journal:  Heliyon       Date:  2019-12-05

7.  Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway.

Authors:  Qianyu Huo; Chen Xu; Yanhong Shao; Qin Yu; Lunhui Huang; Yunde Liu; Huijing Bao
Journal:  Int J Biol Sci       Date:  2021-01-14       Impact factor: 6.580

Review 8.  Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion.

Authors:  Wanjia Tian; Ningjing Lei; Junying Zhou; Mengyu Chen; Ruixia Guo; Bo Qin; Yong Li; Lei Chang
Journal:  Cell Death Dis       Date:  2022-01-18       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.